Navigation Links
Fabre Kramer Pharmaceuticals Receives Decision From FDA on Gepirone ER for Major Depressive Disorder
Date:11/2/2007

HOUSTON, LONDON and RESEARCH TRIANGLE PARK, N.C., Nov. 2 /PRNewswire/ -- Fabre-Kramer Pharmaceuticals Inc. (FKP) and GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has issued a not approvable letter for the new drug application for gepirone extended- release (ER) tablets, submitted for the treatment of adults with major depressive disorder.

The FDA had previously reviewed Phase I through III clinical data involving gepirone ER. In June 2004, the FDA requested an additional positive short-term trial in order to consider gepirone ER for approval as a new antidepressant treatment. Subsequently, FKP successfully conducted a trial in patients with major depressive disorder to respond to the FDA request for an additional positive pivotal study.

Those results were submitted to the FDA in May 2007. The not approvable letter issued today is based on the FDA review of those additional results along with other newly submitted and previously submitted data.

Fabre-Kramer and GlaxoSmithKline entered an agreement in February of this year for collaboration on the worldwide development and commercialization of gepirone extended-release tablets. Fabre-Kramer and GSK are evaluating the response from the FDA to determine appropriate next steps.

About Fabre-Kramer Pharmaceuticals

Fabre-Kramer Pharmaceuticals, headquartered in Houston, Texas, is engaged in acquiring, developing and commercializing psychotropic drugs that have significant market potential. In addition to gepirone ER, Fabre-Kramer has 10 other compounds in various stages of development for indications including depression, anxiety, schizophrenia, Parkinson's disease and insomnia. For more information, visit FKP's website at http://www.fabrekramer.com

About GlaxoSmithKline

GlaxoSmithKline is one of the world's leading research-based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For more information, visit GlaxoSmithKline on the World Wide Web at http://www.gsk.com.


'/>"/>
SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... 2017 Infusion pumps and accessories are ... medications in a controlled, precise and automated manner. ... in critical care, pain management and other applications, ... feel comfortable and pain free. These infusion systems ... to serious life threatening circumstances or even sometimes ...
(Date:1/16/2017)... Wash. , Jan. 16, 2017  Verathon ® Inc., ... announced the launch of new GlideScope ® Spectrum TM ... Dynamic Light Control TM and Ambient Light Reduction TM ... Continue Reading ... ...
(Date:1/16/2017)... --  The Harrington Discovery Institute at University ... has announced the 2017 recipients of Harrington Scholar-Innovator ... whose research shows promise to advance the standard ... – part of The Harrington Project for Discovery ... medicine: to advance early breakthroughs into the clinical ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... January 17, 2017 , ... Neil H. Greco Insurance Agency, a ... communities throughout the region, is launching a charity drive to raise awareness of heart ... the deadliest killer in America, and is responsible for 1 in every 4 deaths ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... Livionex, Inc., ... results of a double blind clinical study for its dental gel that shows significant ... national brand of toothpaste containing triclosan. The study was conducted at the Beckman Laser ...
(Date:1/17/2017)... ... January 17, 2017 , ... The Sharie ... Tyler, has announced the latest beneficiary of their thriving community involvement program. The ... dedicated to fulfilling the dreams of terminally ill patients. Donations to this worthy ...
(Date:1/17/2017)... ... January 17, 2017 , ... Today, FloSports , a global leader in ... agreement as part of a long-term extension of their media partnership. The partnership, which ... some of the sport’s premier events exclusively on FloWrestling.com as well as usage of ...
(Date:1/16/2017)... , ... January 17, 2017 , ... Recently, patients and ... Southwest Michigan, joined other volunteers and organizations in support of the annual Binder Park ... and families dressed up in colorful costumes of all designs coming out to enjoy ...
Breaking Medicine News(10 mins):